Abstract
Children and adolescents are being treated with antipsychotics more often than before, although the risk of adverse events in this age group still remains unclear. Because of increased use of antipsychotics in children and adolescents, their endocrine and metabolic side-effects (weight gain, obesity, and related metabolic deviations) are of particular worrying, especially within pediatric and adolescent population that appears to be at greater risk comparing with adults for antipsychotic-induced metabolic adverse events. In this work we will present the course of treatment of an adolescent girl with psychotic symptoms, within the clinical diagnosis of Organic delusional disorder, who had a considerable weight gain after one year of olanzapine treatment.
MeSH terms
-
Adolescent
-
Anticonvulsants / adverse effects
-
Anticonvulsants / therapeutic use
-
Antipsychotic Agents / adverse effects*
-
Antipsychotic Agents / therapeutic use
-
Benzodiazepines / adverse effects*
-
Benzodiazepines / therapeutic use
-
Body Mass Index
-
Cooperative Behavior
-
Delayed-Action Preparations
-
Dibenzothiazepines / adverse effects
-
Dibenzothiazepines / therapeutic use
-
Drug Substitution
-
Drug Therapy, Combination
-
Epilepsy / diagnosis
-
Epilepsy / drug therapy*
-
Epilepsy / psychology
-
Female
-
Follow-Up Studies
-
Humans
-
Interdisciplinary Communication
-
Lamotrigine
-
Neurocognitive Disorders / diagnosis
-
Neurocognitive Disorders / drug therapy*
-
Neurocognitive Disorders / psychology
-
Olanzapine
-
Quetiapine Fumarate
-
Triazines / adverse effects
-
Triazines / therapeutic use
-
Weight Gain / drug effects*
Substances
-
Anticonvulsants
-
Antipsychotic Agents
-
Delayed-Action Preparations
-
Dibenzothiazepines
-
Triazines
-
Benzodiazepines
-
Quetiapine Fumarate
-
Olanzapine
-
Lamotrigine